Combination of ursodeoxycholic acid and glucocorticoids upregulates the AE2 alternate promoter in human liver cells

Keyphrases

• Primary Biliary Cirrhosis 100%
• Ursodeoxycholic Acid 100%
• Human Liver Cells 100%
• Alternate Promoter 100%
• Monotherapy 50%
• Bicarbonate 50%
• Liver 25%
• Gene Expression 25%
• Treatment Choice 25%
• Hepatocytes 25%
• Beneficial Effects 25%
• Bile Acids 25%
• Chromatin Immunoprecipitation (ChIP) 25%
• Glucocorticoid Receptor 25%
• Disease-associated 25%
• Dexamethasone Treatment 25%
• Cholangiocytes 25%
• Promoter Sequence 25%
• Glucocorticoid Therapy 25%
• Cholestatic Liver Disease 25%
• P300 25%
• Cholestatic Disease 25%
• Lack of Response 25%
• Reporter Assay 25%
• In Vivo Reporter 25%
• Autoimmune Phenomena 25%
• MRNA Isoforms 25%
• HNF1 25%
• UDCA Therapy 25%
• Overlapping Promoters 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Glucocorticoid 100%
• Ursodeoxycholic Acid 100%
• Dexamethasone 100%
• Primary Biliary Cirrhosis 80%
• Monotherapy 40%
• Dicarbonate 40%
• Bile Acid 20%
• Glucocorticoid Receptor 20%
• Liver Disease 20%
• RNA Isoform 20%
• Chromatin Immunoprecipitation 20%
• Hepatocyte Nuclear Factor 1 20%
• Diseases 20%

Biochemistry, Genetics and Molecular Biology

• Promoter Region 100%
• Glucocorticoid 100%
• Dexamethasone 100%
• Ursodeoxycholic Acid 100%
• Gene Expression 20%
• Hepatocyte 20%
• Messenger RNA 20%
• Isoform 20%
• Chromatin Immunoprecipitation 20%
• Pribnow Box 20%
• Glucocorticoid Receptor 20%
• Cholangiocyte 20%
• Bile Acid 20%
• Hepatocyte Nuclear Factor 1 20%